Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
News|Articles|August 6, 2025
9 Cardiology Headlines You Missed in July 2025
Author(s)Patrick Campbell
Fact checked by: Abigail Brooks, MA
July delivered 9 impactful advancements across the gamut of disciplines in cardiology.
Advertisement
Advertisement
Cardiology saw a flurry of activity from the
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement